<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084977</url>
  </required_header>
  <id_info>
    <org_study_id>139/14</org_study_id>
    <nct_id>NCT04084977</nct_id>
  </id_info>
  <brief_title>Dopaminergic Receptors in Sydenham's Chorea</brief_title>
  <official_title>Sydenham's Chorea: Is There a Link Between Neuropsychiatric Symptoms and Anti-dopamine Receptor Autoantibodies?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sydenham's chorea (SC) is a post-streptococcal, neuropsychiatric disorder associated with&#xD;
      anti-neuronal antibodies. The investigators demonstrated elevated anti-D1-receptor (D1R) and&#xD;
      anti-D2-receptor (D2R) antibodies titers compared to controls using ELISA. Similarly, the&#xD;
      investigators found antibodies to surface D2R in neuropsychiatric, autoimmune disorders,&#xD;
      including SC using cell-based assays. The investigators hypothesize that these autoantibodies&#xD;
      cause neuropsychiatric symptoms by inducing intracellular signaling changes resulting in&#xD;
      altered dopaminergic neurotransmission. To check this, the investigators will test whether&#xD;
      sera from patients with SC alter dopaminergic signaling pathways. The investigators will&#xD;
      examine sera from 30 SC patients with active symptoms and 30 age-matched healthy controls.&#xD;
      Patients with SC will be assessed for severity of neuropsychiatric symptoms using UFMG&#xD;
      Sydenham's Chorea Rating Scale. Controls with evidence of streptococcal infections or&#xD;
      autoimmune disorders will be excluded. Sera will be examined for anti-D1R and anti-D2R&#xD;
      antibodies. Signaling studies will assess sera impact on 1) calcium/calmodulin-dependent&#xD;
      protein kinase II activity in human neuronal cells. 2) dopamine D1/D2 receptors signaling&#xD;
      using cAMP assays in transfected cell lines. The investigators will examine the correlation&#xD;
      between modified signaling and clinical symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants:&#xD;
&#xD;
      The investigators will enroll participants with acute Sydenham's chorea (aSC) and age-matched&#xD;
      controls with streptococcal tonsillitis (ST) within the past 4 months and healthy children&#xD;
      (HC) with no a history of a strep infection in the past 6 months and negative throat culture.&#xD;
      Informed consent will be obtained from participants and/ or parents. Children with SC will be&#xD;
      evaluated for SC severity using the USCRS. The investigators will record clinical data&#xD;
      regarding gender, age, duration symptoms, and medical treatments. Controls will be examined&#xD;
      by referring physician to rule out chorea. Sera samples from all participants will be stored&#xD;
      at -70Â°C and shipped to the microbiology and immunology lab, University of Oklahoma Health&#xD;
      Sciences Center (OHSC) on dry ice.&#xD;
&#xD;
      Laboratory testing:&#xD;
&#xD;
      Immunophenotyping for anti-D1R, anti-D2R, anti- LG and anti-tubulin titers and signaling&#xD;
      studies will be performed at the OUHSC microbiology and immunology laboratory.&#xD;
&#xD;
      Autoantibody titers. Sera will be assayed for reactivity with the dopamine D1 and D2&#xD;
      receptors (Human dopamine D1 and D2 receptor membrane antigens, Perkin Elmer-Membrane Target&#xD;
      Systems) in the direct ELISA and assays which include the ELISA competitive inhibition. Anti-&#xD;
      LG and anti-tubulin titers will be tested as well.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      Time will be categorized in order to model non-linear associations among the groups. Means&#xD;
      will be compared among groups using an ANOVA model that included main effects for the time,&#xD;
      participant diagnosis and the interaction between participant diagnosis and time. Modeling&#xD;
      assumptions will be evaluated using residual plots. A natural log transformation of the&#xD;
      antibody measure will be used when there was evidence of non-constant variance across the&#xD;
      groups. If a significant interaction between time and participant group will be found, time&#xD;
      trends will be summarized separately within each participant group. Post-hoc pair-wise&#xD;
      comparisons will be made using Tukey's method to control the type I error rate. A two-sided&#xD;
      0.05 alpha level will be used to define statistical significance. Analyses will be performed&#xD;
      using SAS (SAS Institute Inc., SAS v9.4, Cary, NC: SAS Institute Inc.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>Once at time of initial visit within the first 4 months from onset</time_frame>
    <description>titer levels of anti dopamine receptors (anti-D1 and anti-D2) using ELISA (titer levels are expresed as dilutions i.e. 1:400)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UFMG Sydenham's Chorea Rating Scale</measure>
    <time_frame>Upon presentation when symptomatic, usually within 4 months of onset</time_frame>
    <description>the mean value of the 21 item of clinical chorea rating. Ranging from 0 (=none) to 4 (=severe) for each item</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sydenham Chorea</condition>
  <condition>Strep Throat</condition>
  <arm_group>
    <arm_group_label>Sydenam Chorea (SC)</arm_group_label>
    <description>individuals with SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tonsilitis</arm_group_label>
    <description>children with tonsilitis in the past 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>children wit no tonsilitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Antibody detection</intervention_name>
    <description>detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside</description>
    <arm_group_label>Sydenam Chorea (SC)</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>tonsilitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sera&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        sydenhams chorea according to clinical parameters&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sydenham chora OR strep tonsilitiscontrol without strep tonsilitis OR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neurological disrder autoimmune disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shaare Zedek Medical center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 8, 2019</last_update_submitted>
  <last_update_submitted_qc>September 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

